Abbott Laboratories (ABT) is overvalued and Dexcom Inc (DXCM) is overvalued.
Both trade above our estimate of their intrinsic value. ABT is the closer of the two: -48%, against -61% for DXCM.
Values as of the 22 Sept 2026 close.
Discounting its cash flows at 8.3% (average of 3 methods) values the shares at $70.00; the price of $103.69 is 48% above that value, and 78% of that value comes from beyond year five.
Leak Score 57/100 on 10 of 12 signals
Discounting its cash flows at 11.4% (average of 3 methods) values the shares at $55.75; the price of $89.53 is 61% above that value, and 70% of that value comes from beyond year five.
Leak Score 68/100 on 9 of 12 signals
| Metric | ABT | DXCM |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Price | $103.69 | $89.53 |
| Intrinsic value | $70.00 | $55.75 |
| Margin of safety | -48% | -61% |
| Leak Score | 57/100 (10/12) | 68/100 (9/12) |
| Market cap | $179.4B | $33.8B |
| Revenue growth, 5 years | 5.1% | 19.3% |
| Operating margin | 16.4% | 22.9% |
| Net margin | 11.6% | 20.1% |
| Return on equity | 10.6% | 38.5% |
| Debt to equity | 0.64 | 0.53 |
| P/E | 33.5x | 35.3x |
| Forward P/E | 17.1x | 28.7x |
| P/B | 3.5x | 12.9x |
| Dividend yield | 2.5% | — |